Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | DRD1 | P21728 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22365583 | 1.00 | NPC1 (0.43) | NPC1MAPTRAB9ASMN1; SMN2MAPK1 | |
| SCHEMBL2367798 | 0.85 | NPC1 (0.58) | NPC1MAPTRAB9ASMN1; SMN2MAPK1 | |
| SCHEMBL3415364 | 0.85 | NPC1 (0.58) | NPC1MAPTRAB9ASMN1; SMN2MAPK1 | |
| SCHEMBL29528441 | 0.85 | NPC1 (0.58) | NPC1MAPTRAB9ASMN1; SMN2MAPK1 | |
| SCHEMBL3954455 | 0.85 | NPC1 (0.58) | NPC1MAPTRAB9ASMN1; SMN2MAPK1 | |
| SCHEMBL21500179 | 0.84 | NPC1 (0.37) | NPC1MAPTRAB9ASMN1; SMN2MAPK1 | |
| SCHEMBL14498451 | 0.82 | NPC1 (0.44) | NPC1MAPTRAB9ASMN1; SMN2MAPK1 | |
| SCHEMBL14347242 | 0.82 | HTT (0.44) | NPC1MAPTRAB9ASMN1; SMN2MAPK1 | |
| SCHEMBL18934250 | 0.80 | HTT (0.40) | NPC1MAPTRAB9ASMN1; SMN2MAPK1 | |
| SCHEMBL28004074 | 0.80 | HTT (0.40) | NPC1MAPTRAB9ASMN1; SMN2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210323970-A1 | METHOD FOR PRODUCING A SPIROOXINDOLE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2021-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210323970-A1 | METHOD FOR PRODUCING A SPIROOXINDOLE DERIVATIVE | MDM2, TP53, RB1 | NPC1 4482/4885MAPT 4257/4885RAB9A 2301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.